Benefits of enhanced infection prophylaxis at antiretroviral therapy initiation by cryptococcal antigen status.

ABSTRACT:

Objectives

To assess baseline prevalence of cryptococcal antigen (CrAg) positivity; and its contribution to reductions in all-cause mortality, deaths from cryptococcus and unknown causes, and new cryptococcal disease in the REALITY trial.

Design

Retrospective CrAg testing of baseline and week-4 plasma samples in all 1805 African adults/children with CD4+ cell count less than 100 cells/μl starting antiretroviral therapy who were randomized to receive 12-week enhanced-prophylaxis (fluconazole 100 mg/day, azithromycin, isoniazid, cotrimoxazole) vs. standard-prophylaxis (cotrimoxazole).

Methods

Proportional hazards models were used to estimate the relative impact of enhanced-prophylaxis vs. standard-cotrimoxazole on all, cryptococcal and unknown deaths, and new cryptococc

SUBMITTER: Pett SL 

PROVIDER: S-EPMC7613319 | biostudies-literature | 2021 Mar

REPOSITORIES: biostudies-literature